SEC Form 4 · accession 0001140361-15-038096

ORAMED PHARMACEUTICALS INC. · ORMP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

10% Owner

10% Owner

Period of report

Oct 16, 2015

Accepted (ET)

Oct 20, 2015 · 5:09 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001176309

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	896,364	I	By Regals Fund LP

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Call Option (Right to Buy)^F1	$10.00	Oct 16, 2015	P	1,192	A	Oct 16, 2015	May 20, 2016	Common Stock	119,200	1,192	I
Call Option (Right to Buy)^F1	$10.00	Oct 19, 2015	P	600	A	Oct 19, 2015	May 20, 2016	Common Stock	60,000	1,792	I
Call Option (Right to Buy)^F1	$10.00	Oct 20, 2015	P	11	A	Oct 20, 2015	May 20, 2016	Common Stock	1,100	1,803	I

F1This Form 4 is filed jointly by Regals Fund LP (the "Fund"), Regals Capital Management LP ("Regals Management"), and David M. Slager (collectively, the "Reporting Persons"). Mr. Slager is Managing Member of the general partner of Regals Management. Regals Management is the investment manager of the Fund. The securities reported herein are held for the account of the Fund. Accordingly, each of the Reporting Persons may be deemed to be a beneficial owner of the securities owned by the Fund for purposes of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended (the "Act"). Pursuant to Rule 16a-1(a)(4) under the Act, Regals Management and Mr. Slager disclaim beneficial ownership in the securities owned by the Fund except to the extent, if any, of their pecuniary interest therein.